Entera Bio Ltd (ENTX): Price and Financial Metrics


Entera Bio Ltd (ENTX): $1.51

-0.11 (-6.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENTX POWR Grades


  • ENTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.78% of US stocks.
  • ENTX's strongest trending metric is Stability; it's been moving up over the last 49 days.
  • ENTX ranks lowest in Quality; there it ranks in the 2nd percentile.

ENTX Stock Summary

  • Entera Bio Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 8.29% of US listed stocks.
  • For ENTX, its debt to operating expenses ratio is greater than that reported by merely 7.37% of US equities we're observing.
  • With a price/sales ratio of 137.12, Entera Bio Ltd has a higher such ratio than 98.11% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Entera Bio Ltd, a group of peers worth examining would be TTNP, SDGR, PSNL, BCYC, and UTHR.
  • Visit ENTX's SEC page to see the company's official filings. To visit the company's web site, go to www.enterabio.com.

ENTX Valuation Summary

  • ENTX's price/sales ratio is 257; this is 6663.16% higher than that of the median Healthcare stock.
  • ENTX's price/earnings ratio has moved down 1.1 over the prior 39 months.
  • ENTX's price/sales ratio has moved NA NA over the prior 39 months.

Below are key valuation metrics over time for ENTX.

Stock Date P/S P/B P/E EV/EBIT
ENTX 2021-08-31 257.0 5.5 -7.5 -6.0
ENTX 2021-08-30 253.8 5.4 -7.4 -6.0
ENTX 2021-08-27 254.9 5.4 -7.4 -6.0
ENTX 2021-08-26 256.1 5.4 -7.4 -6.0
ENTX 2021-08-25 264.4 5.6 -7.7 -6.3
ENTX 2021-08-24 266.5 5.7 -7.7 -6.3

ENTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENTX has a Quality Grade of F, ranking ahead of 3.86% of graded US stocks.
  • ENTX's asset turnover comes in at 0.032 -- ranking 348th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ENTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.032 0.521 5.412
2021-03-31 0.039 0.531 4.464
2020-12-31 0.032 0.427 4.177
2020-09-30 0.039 0.588 4.010
2020-06-30 0.032 0.453 4.665
2020-03-31 0.023 0.094 3.818

ENTX Price Target

For more insight on analysts targets of ENTX, see our ENTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

ENTX Stock Price Chart Interactive Chart >

Price chart for ENTX

ENTX Price/Volume Stats

Current price $1.51 52-week high $6.60
Prev. close $1.62 52-week low $1.43
Day low $1.44 Volume 63,900
Day high $1.69 Avg. volume 69,694
50-day MA $2.21 Dividend yield N/A
200-day MA $2.97 Market Cap 35.79M

Entera Bio Ltd (ENTX) Company Bio


Entera Bio Ltd operates as a biotechnology company. The Company specializes in the oral delivery of molecules and biologics. Entera Bio also develops candidates for the treatment of osteoporosis. Entera Bio serves patients in the United States and Israel.


ENTX Latest News Stream


Event/Time News Detail
Loading, please wait...

ENTX Latest Social Stream


Loading social stream, please wait...

View Full ENTX Social Stream

Latest ENTX News From Around the Web

Below are the latest news stories about Entera Bio Ltd that investors may wish to consider to help them evaluate ENTX as an investment opportunity.

Entera Bio to Present at Aegis Virtual Conference on February 23rd

BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company’s Chief Executive Officer, Spiros Jamas, Sc.D., will present a company overview at the Aegis Capital Corp. Virtual Conference on February 23rd at 3:30 PM Eastern time. Entera’s presentation, which can be found HERE, will include details of the Company’s upcoming pivotal Phase 3 study for its l

Yahoo | February 17, 2022

Maxim Group Thinks Entera Bio’s Stock is Going to Recover

Maxim Group analyst Jason McCarthy maintained a Buy rating on Entera Bio (ENTX – Research Report) on February 2 and set a price target of $6.00. The company's shares closed last Friday at $2.30, close to its 52-week low of $1.22. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Entera Bio with a $6.

Christine Brown on TipRanks | February 6, 2022

Entera Bio (ENTX) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Entera Bio (ENTX – Research Report) yesterday and set a price target of $10.00. The company's shares closed last Wednesday at $2.93. According to TipRanks.com, McCarthy 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.7% and a 22.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Entera Bio is a Moderate Buy with an average price target of $10.50.

Brian Anderson on TipRanks | January 5, 2022

Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

‒ Company plans to initiate multi-national Phase 3 Trial in 2022 ‒BOSTON and JERUSALEM, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), today announced it has concluded its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on EB613, its oral formulation of human parathyroid hormone (1-34), or PTH, for the treatment of osteoporosis and defined the path for Phase 3 development of EB613, confirming that a fracture study will not be necessary and that

Yahoo | January 4, 2022

Financial Analysis: Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX)

Kodiak Sciences (NASDAQ:KOD) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Analyst Ratings This is a summary of recent ratings and price targets for Kodiak Sciences and []

Transcript Daily | November 21, 2021

Read More 'ENTX' Stories Here

ENTX Price Returns

1-mo -32.29%
3-mo -45.88%
6-mo -47.57%
1-year -75.12%
3-year -55.98%
5-year N/A
YTD -46.36%
2021 160.65%
2020 -49.53%
2019 -29.84%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6174 seconds.